Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, ...

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Camurus announces positive topline results for CAM2056, semaglutide monthly depot: Lund, Sweden Tuesday, November 11, 2025, 16:00 Hrs [IST] Camurus, an international, science-led ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd are preparing to enter the fast-growing market for Semaglutide — a ...

Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company's monthly FluidCrystal® semaglutide formulation, ...

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for ...

How effective is Wegovy at treating MASH? Novo Nordisk announced the results of the ESSENCE phase 3 trial at the American ...

The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...